Clinical Trials Browser

Phase 2/3 × Interventional × Pemetrexed × Clear all

NCT06712316 2026-03-17

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-03-17

MountainTAP-29

Phase 2/3 Recruiting

Lung Neoplasms

NCT07100080 2026-03-03

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06236438 2026-02-23

LIVIGNO-4

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung

NCT07131319 2026-02-02

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2/3 Completed

520 enrolled 16 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Phase 2/3 Not yet recruiting

Non-squamous Non-small Cell Lung Cancer

NCT03380468 2023-07-20

ECTOP-1004

Phase 2/3 Unknown

Adenocarcinoma of Lung, Lung Neoplasms

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Phase 2/3 Unknown

NSCLC

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Nonsquamous Non-small Cell Lung Cancer

NCT01774578 2020-05-28

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Phase 2/3 Terminated

545 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02777788 2017-10-10

TCM

Phase 2/3 Unknown

Neoplasms

NCT01383148 2017-01-05

TIME

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01769066 2016-02-23

Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC

Phase 2/3 Completed

NSCLC

NCT01481259 2012-07-03

Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung